Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00244140 · ClinicalTrials.gov registry record · Phase 3
Ultravist: Safety and Efficacy in Computed Tomography of Head and Body
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 435
- Enrollment target
NCT00244140 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 435 participants.
The verdict
NCT00244140, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 435 participants
- Enrollment target
Study Summary
This is a research study involving the use of a contrast agent called Ultravist Injection. Ultravist, the study drug, is used to improve the pictures obtained using computed tomography (CT). Ultravist acts like a dye to make CT pictures brighter and easier to read. In the case of this study, it will be injected into a vein in the patient's arm; from there, it travels through the blood stream and to the areas to be examined. CT scans will then be taken of the patient's head and/or body as ordered by his/her physician. Phase IIIb Study to Document the Safety and Efficacy of Ultravist 370 mg I/ml, When Administered Intravenously, in Volumes up to 162.2 ml, for Clinically Indicated Contrast Enhanced Computed Tomography (CECT) of the Head and/or Body
Interventions
- DRUG Iopromide 370 mg I/mL
- DRUG Iopromide 300 mg I/mL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 435 participants |
| Start Date | 2005-10 |
| Est. Completion | 2008-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00244140
The ClinicalTrials.gov registry entry for NCT00244140 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 435 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Iopromide 370 mg I/mL is the first listed.
NCT00244140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00244140 about?
NCT00244140 is a clinical study titled "Ultravist: Safety and Efficacy in Computed Tomography of Head and Body". This is a research study involving the use of a contrast agent called Ultravist Injection. Ultravist, the study drug, is used to improve the pictures obtained using computed tomography (CT). Ultravist acts like a dye to make CT pictures brighter and easier to read. In the case of this study, it will...
What is the current status of trial NCT00244140?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 435 participants. The study started on 2005-10. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00244140?
The interventions under investigation include: Iopromide 370 mg I/mL (DRUG), Iopromide 300 mg I/mL (DRUG).
Who is sponsoring clinical trial NCT00244140?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.